Health Care
Resmed Inc (RMD)
ResMed Inc (RMD) is a global leader in respiratory therapies and sleep apnea solutions, operating worldwide with a strong presence in Australia. Key products include CPAP (Continuous Positive Airway Pressure) machines like AirSense and AirFit masks. The company is headquartered in San Diego, USA, but listed on the ASX.
Market Cap
A$52.0B
Shares on Issue
N/A
Price Chart
AI Analysis
ResMed currently holds a dominant position in the sleep apnea market, with recent performance indicating steady revenue growth driven by increasing global demand for respiratory products. Notable metrics include a market cap of A$52.0B and a long listing history on the ASX since 25/11/1999.
Looking ahead, ResMed's growth is expected to be fueled by expanding into emerging markets and leveraging technology like connected healthcare devices. Strategic acquisitions and R&D in chronic obstructive pulmonary disease (COPD) treatments are key strategic directions.
Bull Case
- • Strong brand loyalty and market dominance in sleep apnea treatments provide a stable revenue base.
- • Growing awareness and diagnosis rates of sleep disorders globally offer significant untapped market potential.
- • Continuous innovation in connected health technology enhances product attractiveness and customer retention.
Bear Case
- • Intense competition from emerging players in the respiratory therapy market could erode margins.
- • Regulatory changes or reimbursement policy shifts in key markets (e.g., the US, Australia) might impact profitability.
- • Dependence on a few core product lines leaves the company vulnerable to technological obsolescence or patent expirations.
Recent Announcements
Statement of CDIs on issue - RMD
4 Statement of changes in beneficial ownership
144 Report of proposed sale of securities
Form 10-Q for the Quarter Ended December 31, 2025
🚨 Price SensitiveRMD has released its quarterly financial report (Form 10-Q) for Q4 ending Dec 31, 2decuate, detailing company performance and future outlook.
Dividend/Distribution - RMD
FAQs
What does RMD do?
ResMed develops and manufactures devices for respiratory disorders, notably sleep apnea, with products including CPAP machines and masks.
Is RMD a good investment?
ResMed offers a strong market position and growth prospects, but investors should weigh these against potential regulatory and competitive risks.
What drives RMD's share price?
Key drivers include earnings reports, new product approvals, regulatory changes in healthcare reimbursement, and global demand for respiratory therapies.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.